Pharmaceutical News

RSS

Wellness Formulations introduces Dermal Renu Sunshield

Wellness Formulations, LLC, a leader in anti-glycation research and product development, has launched Dermal Renu® Sunshield daily wear SPF 15 sunscreen. This mineral based sunscreen provides broad-spectrum protection from sun damage caused by UVA/UVB rays, while fighting the signs of aging through a unique combination of anti-glycation agents, antioxidants, moisturizing elements, peptides, and botanical extracts.

30 Mar 2010

Cumberland Pharmaceuticals submits Acetadote sNDA for non-acetaminophen acute liver failure

Cumberland Pharmaceuticals Inc. has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration for the use of Acetadote® (acetylcysteine) Injection in patients with non-acetaminophen acute liver failure. Acetadote was launched by Cumberland in 2004 as the first U.S.-approved injectable drug to treat acetaminophen overdose.

30 Mar 2010

Britain popping “pills for every ill”, says research

A new study reports that Britons are turning to prescription drugs for every illness, minor or major. This recent paper titled “A Pill for Every Ill”, published in Social Science & Medicine journal says that while two decades earlier average number of prescriptions dispensed per person was only eight, it is more than 16 now.

30 Mar 2010

GSK re-submits sNDA for Avodart to FDA

GlaxoSmithKline announced today that it has re-submitted the supplemental New Drug Application for Avodart® (dutasteride) for prostate cancer risk reduction among men at increased risk of developing the disease to the US Food and Drug Administration.

30 Mar 2010

NICE appraisal committee publishes preliminary recommendation of Multaq for AF

Sanofi-aventis announced today that the National Institute for Health and Clinical Excellence (NICE) in England and Wales, has just published a new appraisal consultation document for Multaq(R) (dronedarone) indicating its intention to recommend Multaq(R) use for the management of patients with atrial fibrillation.

30 Mar 2010

Decision Resources: Only 52.2% of first-line Alzheimer's disease patients prescribed AChEI

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that while approximately 70 percent of surveyed physicians' newly diagnosed patients have mild-to-moderate Alzheimer's disease, only 52.2 percent of first-line patients are prescribed an acetylcholinesterase inhibitor.

30 Mar 2010

Preclinical study of DAS181 for treatment and prevention of ILI published

NexBio, Inc. announced today the publication in the Journal of Infectious Diseases of a preclinical study suggesting that treatment with DAS181 (Fludase®) may reduce the risk of secondary bacterial pneumonia following influenza virus infection.

30 Mar 2010

Potential new target for treating HCV infection

A team of scientists including University of Utah researchers has discovered that binding of a potent inhibitor of the hepatitis C virus to the genetic material of the virus causes a major conformational change that may adversely affect the ability of the virus to replicate.

30 Mar 2010

Cangene extends botulism antitoxin contract with BARDA

Cangene Corporation today reports that it has signed a no-cost modification to extend its botulism antitoxin contract with the Biomedical Advanced Research and Development Authority ("BARDA"). BARDA is the department within the U.S. Department of Health and Human Services that manages the two biodefence-related, stockpiling contracts Cangene has with HHS.

30 Mar 2010

Cephalon receives FDA Complete Response Letter for NUVIGIL supplemental new drug application

Cephalon, Inc. today announced the company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for its supplemental new drug application for NUVIGIL® (armodafinil) Tablets [C-IV] in the treatment of patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel.

30 Mar 2010

Alcon acquires right to market DUREZOL ophthalmic corticosteroid in U.S.

Alcon, the world's leader in eye care, announced today that it received regulatory approval and finalized the acquisition of the rights in the United States for DUREZOL™ emulsion and the global rights, excluding Latin America, for ZYCLORIN™ from Sirion Therapeutics, Inc.

30 Mar 2010

GSK offers free vaccines for low income adults without insurance coverage

GlaxoSmithKline today announced the launch of the GSK Vaccines Access Program, which will provide the company's adult vaccines free of charge to eligible, low income individuals who do not have insurance coverage for vaccines. The program will cover the company's FDA-approved vaccines for Hepatitis A, Hepatitis B, tetanus, diphtheria, and pertussis for eligible persons ages 19 and older.

29 Mar 2010

Generex Biotechnology announces FDA Expanded Access Treatment IND Program for Generex Oral-lyn

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has expanded its plans for its United States Food and Drug Administration (FDA) Expanded Access Treatment IND Program for its flagship product, Generex Oral-lyn™, to include licensed and qualified Nurse Practitioners in the United States.

29 Mar 2010

Oxygen Biotherapeutics commences distributing newly formulated Dermacyte Oxygen Concentrate

Oxygen Biotherapeutics, Inc. today announced that the company has begun distribution for its newly formulated Dermacyte™ Oxygen Concentrate for the beauty and skin care market. The over-the-counter product is a scientifically designed perfluorocarbon concentrate to enhance oxygen delivery to skin.

29 Mar 2010

Parenteral Biotech to supply and distribute Sinovac Biotech's Anflu and PANFLU.1 vaccines in India

Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today it has entered into exclusive license, supply and distribution agreements with Parenteral Biotech Ltd., a subsidiary of Parenteral Drugs (India), Ltd., an India-based pharmaceutical company. Pursuant to the agreements, Parenteral is authorized to register, supply and distribute Sinovac's Anflu (seasonal influenza vaccine) and PANFLU.1 (H1N1 vaccine) to the government of India and private market in India. Currently, the registration process is ongoing in India.

29 Mar 2010

PROCAPS granted exclusive rights to commercialize Pro-Pharmaceuticals' DAVANAT in Colombia

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that it has granted PROCAPS S.A. exclusive rights to market and sell DAVANAT® to treat cancer in Colombia, South America. Phase ll clinical trial results for late-stage colorectal cancer patients demonstrate that when DAVANAT® is co-administered with the chemotherapy drug 5-FU, survival increased by 46% over the best standard of care and reduced serious adverse events associated with chemotherapy.

29 Mar 2010

Redpoint Bio announces revenue of $1.9M for full-year 2009

Redpoint Bio Corporation, a company focused on the development of healthier foods and beverages and new approaches to the treatment of diabetes and obesity, today announced financial and operational results for the quarter and year ended December 31, 2009.

29 Mar 2010

Naturalhealthylife.co.uk celebrates National Garlic Day

Naturalhealthylife.co.uk, the official UK site for herbal supplements made by Klosterfrau, are celebrating National Garlic Day on Monday 19th April. Klosterfrau is a leading manufacturer of herbal healthcare products.

29 Mar 2010

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that Erbitux® (cetuximab) can now be used in Japan in combination with chemotherapy in the 1st-line treatment for patients with epidermal growth factor receptor -expressing, curatively unresectable (inoperable), advanced or recurrent colorectal cancer carrying the KRAS wildtype gene.

29 Mar 2010

Scientists link gene expression profiling effort to identify potential novel therapeutic for ALS

In an article published in Nature Genetics today, scientists at the ALS Therapy Development Institute describe how they have linked an unbiased gene expression profiling effort to the identification and successful preclinical testing of a potential novel therapeutic for amyotrophic lateral sclerosis.

29 Mar 2010

Pharmaceutical News

Wellness Formulations introduces Dermal Renu Sunshield

Cumberland Pharmaceuticals submits Acetadote sNDA for non-acetaminophen acute liver failure

Britain popping “pills for every ill”, says research

GSK re-submits sNDA for Avodart to FDA

NICE appraisal committee publishes preliminary recommendation of Multaq for AF

Decision Resources: Only 52.2% of first-line Alzheimer's disease patients prescribed AChEI

Preclinical study of DAS181 for treatment and prevention of ILI published

Potential new target for treating HCV infection

Cangene extends botulism antitoxin contract with BARDA

Cephalon receives FDA Complete Response Letter for NUVIGIL supplemental new drug application

Alcon acquires right to market DUREZOL ophthalmic corticosteroid in U.S.

GSK offers free vaccines for low income adults without insurance coverage

Generex Biotechnology announces FDA Expanded Access Treatment IND Program for Generex Oral-lyn

Oxygen Biotherapeutics commences distributing newly formulated Dermacyte Oxygen Concentrate

Parenteral Biotech to supply and distribute Sinovac Biotech's Anflu and PANFLU.1 vaccines in India

PROCAPS granted exclusive rights to commercialize Pro-Pharmaceuticals' DAVANAT in Colombia

Redpoint Bio announces revenue of $1.9M for full-year 2009

Naturalhealthylife.co.uk celebrates National Garlic Day

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

Scientists link gene expression profiling effort to identify potential novel therapeutic for ALS

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News